Figure 1.
Figure 1. Baseline SF-36 scores for AL amyloidosis patients compared with age-matched US population norms. Surveys were obtained at the initial evaluation on 544 patients (gray squares) and the mean SF-36 scores were compared with age-matched US population norms (black circles). The mean scores of 251 patients who underwent treatment with HDM/SCT (light gray triangles) and those of 210 patients who were deemed to be ineligible for such treatment (gray diamonds) are also indicated. All means for the patients are significantly (P < .001) below age-matched US population norms, indicated by underlines, except for BP in the treated patients. The numeric mean scores and P values are provided in Table S1 (see the Supplemental Tables link at the top of the online article on the Blood website).

Baseline SF-36 scores for AL amyloidosis patients compared with age-matched US population norms. Surveys were obtained at the initial evaluation on 544 patients (gray squares) and the mean SF-36 scores were compared with age-matched US population norms (black circles). The mean scores of 251 patients who underwent treatment with HDM/SCT (light gray triangles) and those of 210 patients who were deemed to be ineligible for such treatment (gray diamonds) are also indicated. All means for the patients are significantly (P < .001) below age-matched US population norms, indicated by underlines, except for BP in the treated patients. The numeric mean scores and P values are provided in Table S1 (see the Supplemental Tables link at the top of the online article on the Blood website).

Close Modal

or Create an Account

Close Modal
Close Modal